Climb Bio share price logo

Climb Bio

NASDAQ: CLYM

Small Cap

$16.07

-1.77

(-9.92%)

as on

Climb Bio Stock Performance

as on August 27, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $16.01
    $17.80
    downward going graph

    0.37%

    Downside

    10.77%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.54
    $18.33
    downward going graph

    90.42%

    Downside

    14.06%

    Upside

    downward going graph

Climb Bio share price movements today

Previous Close
$17.84
Open
$17.72
Volume
1.6M
Market Cap
$942.0M
Day's Low - High
$16.01 - $17.80
52 Week Low - High
$1.54 - $18.33

Climb Bio Historical Returns

1 Month Return
+ 39.48 %
3 Month Return
+ 49.16 %
1 Year Return
+ 680.74 %
3 Year Return
0 %
5 Year Return
0 %

Climb Bio Stock Fundamentals & Key Indicators

Check Climb Bio market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$942.0M

EPS (TTM)

-0.7788

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-27.10%

Climb Bio vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Climb Bio with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$942.0MNANA0.00%NA
BUY$45.3B641.42%NA0.00%NA
BUY$138.8B176.54%31.9535.00%NA
BUY$55.4B-58.45%NA-141.43%NA
BUY$85.3B25.67%20.6227.87%44.39%

Stock Returns calculator for Climb Bio Stock including INR - Dollar returns

The Climb Bio stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Climb Bio investment value today

Current value as on today

₹7,65,618

Returns

₹6,65,618

(+665.62%)

Returns from Climb Bio Stock

₹6,03,282 (+603.28%)

Dollar Impact

₹62,336 (+62.34%)

Analyst Recommendation on Climb Bio Stock

Based on 11 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 11 analysts, 100% of analysts recommend a 'BUY' rating for Climb Bio. Average target price of $23.5

Indian Investors' Interest in Climb Bio Stock

Search interest for Climb Bio Stock has increased by 26% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:26% versus previous 30 day period

Climb Bio Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
0
0
0
0
-
Operating Income
-3
-56
-11
-10
-23
-10
-14
-19
-15
-15
EBITDA
-1
-54
-8
-8
-20
-8
-12
-17
-13
-15
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
0
0
0
0
0
Income Before Tax
-1
-54
-8
-8
-20
-8
-12
-17
-13
-13
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-1
-54
-8
-8
-20
-8
-12
-17
-13
-13
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Climb Bio Annual Profit & Loss

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
0
Operating Income
-20
-35
-45
-40
-82
-67
EBITDA
-11
-47
-45
-35
-30
-59
Interest Expense
-
-
-
-
-
-
Depreciation
-
-
-
-
-
0
Income Before Tax
-20
-47
-45
-35
-73
-59
Income Tax Expense
-
-
-
-
-
-
Net Income
-20
-47
-45
-35
-73
-59
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Climb Bio Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-54
-8
-8
-20
-8
-12
-17
-13
-13
Operating Cash Flow
0
-7
-5
-15
-11
-12
-15
-14
-10
Investing Cash Flow
-9
-71
-53
-42
4
15
25
-12
-57
Financing Cash Flow
128
2
0
-
-
-
0
0
103
Change in Cash
118
-76
-58
-58
-6
3
9
-27
35

Climb Bio Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-20
-47
-45
-35
-73
-59
Operating Cash Flow
-14
-36
-37
-20
-15
-54
Investing Cash Flow
8
-114
34
68
-121
2
Financing Cash Flow
4
177
-
0
130
0
Change in Cash
0
26
-3
49
-5
-51

Mutual Funds that own Climb Bio Stock

Check out the Mutual Funds with significant holdings in Climb Bio.

Funds
Holdings
Shares Held
T. ROWE PRICE HEALTH SCIENCES FUND, INC.
2.556602%
1468417
VANGUARD INDEX FUNDS
1.998554%
1147895
Fidelity Concord Street Trust
0.450173%
258563
Bridgeway Funds, Inc.
0.215543%
123800
DFA INVESTMENT DIMENSIONS GROUP INC
0.087836%
50450

Global Institutional Holdings in Climb Bio

Funds
Holdings
Peter Kolchinsky
19.68%
Vanguard
3.73%
Michael Rockefeller
2.75%
iShares
2.39%
Richard Driehaus
1.38%

Insights on Climb Bio

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, CLYM has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, CLYM stock has moved up by 680.7%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, CLYM has outperformed top 5 stocks with highest market-cap in its industry

About Climb Bio

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
OrganisationClimb Bio
Headquarters20 William Street, Wellesley Hills, MA, United States, 02481
IndustryBiotechnology
CEODr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
E-voting on sharesClick here to vote

Key Management of Climb Bio

Name

Title

Ms. Chandra Adams J.D.

Senior VP, General Counsel & Secretary

Ms. Ashley Jones

Senior Vice President of People & Workforce Strategy

Ms. Janaki M. Subramanyam M.Sc.

VP & Head of Regulatory Affairs

Dr. Edgar D. Charles M.D., M.Sc.

Chief Medical Officer

Ms. Theresa Donegan M.S.

Vice President & Head of Quality

Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc

CEO, President & Director

Dr. Perrin Wilson B.S., Ph.D.

Chief Business Officer

Mr. Adam Villa

Senior Vice President of Technical Operations

Dr. Susan Altschuller M.B.A., Ph.D.

CFO & Principal Accounting Officer

FAQs

What is Climb Bio share price today?

Climb Bio share price today is $16.07 as on at the close of the market. Climb Bio share today touched a day high of $17.80 and a low of $16.01.

What is the 52 week high and 52 week low for Climb Bio share?

Climb Bio share touched a 52 week high of $18.33 on and a 52 week low of $1.54 on . Climb Bio stock price today i.e. is closed at $16.07,which is 12.33% down from its 52 week high and 943.51% up from its 52 week low.

What is Climb Bio's market capitalisation today?

Climb Bio market capitalisation is $0.00T as on .

How to invest in Climb Bio Stock (CLYM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Climb Bio on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Climb Bio Shares that will get you 0.0933 shares as per Climb Bio share price of $16.07 per share as on August 27, 2026 at 1:29 am IST.

What is the minimum amount required to buy Climb Bio Stock (CLYM) from India?

Indian investors can start investing in Climb Bio (CLYM) shares with as little as ₹95.402 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹954.02 in Climb Bio stock (as per the Rupee-Dollar exchange rate as on ). Based on Climb Bio share’s latest price of $16.07 as on August 27, 2026 at 1:29 am IST, you will get 0.6223 shares of Climb Bio. Learn more about fractional shares .